



Comorbidity and Autoimmune Connective Tissue Disorders: From Bench to Bedside

Guest Editors:

Dr. Ilaria Mormile

Department of Translational
Medical Sciences, University of
Naples Federico II, Via S. Pansini
5, 80131 Naples, Italy

Prof. Dr. Francesca Wanda Rossi

Department of Translational
Medical Sciences (DiSMeT),
Center for Basic and Clinical
Immunology Research (CISI),
WAO Center of Excellence,
University of Naples Federico II,
80131 Naples, Italy

Deadline for manuscript
submissions:

closed (31 March 2024)

Message from the Guest Editors

Dear Colleagues,

Autoimmune connective tissue disorders are often associated with one or more comorbidities such as musculoskeletal, cardiovascular, pulmonary, or gastrointestinal diseases. Although some of these associations are well known, the relationship between comorbidities, polypharmacy, and symptoms of the underlying disease burden is often unclear. In addition, the diagnosis of many comorbidities of autoimmune connective tissue disorders is usually conducted at a late stage, and thus associated with poor prognosis. With this broad research theme in mind, we welcome manuscripts from several perspectives, including basic, clinical and translational research, in order to provide important insight into the features, biomarkers and predictive factors of comorbidities in autoimmune connective tissue disorders. Studies on safety, efficacy, and recommendations for vaccination in individuals with autoimmune diseases and comorbidities are also welcome. We look forward to receiving your contributions to the Special Issue.

Dr. Ilaria Mormile

Dr. Francesca Wanda Rossi

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)